Overexpression of BCL2 and BAX following BFM induction therapy predicts ch-ALL patients’ poor response to treatment and short-term relapse


The identification of childhood acute lymphoblastic leukemia (ch-ALL) patients who are at a higher risk of chemotherapy resistance and relapse is essential for successful treatment decisions, despite the application of novel therapies. The aim of the study is the evaluation of BCL2 and BAX expression for the prognosis of ch-ALL patients treated with Berlin… (More)
DOI: 10.1007/s00432-015-1982-6

8 Figures and Tables


  • Presentations referencing similar topics